EGFR and non-small cell lung carcinoma: The IPASS study (the Iressa Pan-Asia study) is a landmark study on NSCLC, demonstrating the superiority of TKI as a first-line treatment compared to chemotherapy for EGFR mutant patients with respect to progression-free survival (PFS) (24).